Want to see TVRD full AI Analyst Report?
TVRD Stock Chart & Stats
$3.39
--
Market closed
$3.39
--
Day’s Range― - ―
52-Week Range$1.50 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$18.95M
Enterprise Value$4.53M
Total Cash (Recent Filing)$30.81M
Total Debt (Recent Filing)$201.00K
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 13, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.24
Enterprise Value/Revenue1.76
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$9.80Price Target Upside189.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt relative to equity reduces near-term solvency risk and preserves balance-sheet optionality. For a clinical-stage biotech, low leverage supports the ability to raise non-debt capital, withstand R&D volatility, and avoid immediate refinancing pressure over the next several months.
Improving Cash Burn TrendA material reduction in cash burn in 2025 versus 2024 indicates management is taking cost or program actions that improve runway. While still negative, a sustained lower burn rate lengthens time to the next financing and increases the chance of executing near-term clinical milestones without immediate dilution.
Governance And Board StabilityRecent elections and auditor ratification show conventional governance alignment and board continuity. Strong governance and an independent auditor improve oversight, help in securing investor confidence for future financings, and support disciplined strategic choices across clinical and financing decisions.
Bears Say
No Commercial RevenueThe company reports zero revenue in 2025, meaning no product-derived cash inflows. As a clinical-stage biotech, sustained absence of commercial sales makes the business fully dependent on development success and external capital, increasing long-term financing and execution risk.
Persistent Negative Cash GenerationConsistently negative operating and free cash flow demonstrates the company cannot self-fund operations. Persistent cash burn requires repeated financing, which can dilute shareholders, constrain R&D sequencing, and raise the risk that programs are delayed or reshaped by funding availability.
Multi-year Losses And Past Equity ErosionHistorical negative equity and sustained net losses signal prior capital erosion and limited financial flexibility. Shrinking assets and past deficits increase dependency on external capital and highlight execution challenges that could persist absent successful clinical or financing outcomes.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $1.50 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $18.95M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 37 days.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD Stock 12 Month Forecast
Average Price Target
$9.80
▲(189.09% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
8.15% Insiders
7.98% Mutual Funds
11.87% Other Institutional Investors
67.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---